We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


Assessing bioequivalence for nasal sprays and dry powder inhalers


Assessing bioequivalence for nasal sprays and dry powder inhalers

While the advantages of Orally Inhaled and Nasal Drug products for both systemic and locally acting drug delivery are widely understood, the challenge remains to develop products with the required performance.

The property of the formulation, the design of the delivery device and the actuation characteristics of the target user group all influence dispersion behaviour in case of OINDP products like nasal sprays, dry powder inhalers. Physical parameters of the drug and excipients like particle size, shape, density, charge etc. plays a critical role in drug delivery to the respiratory tract and its bioavailability.

Determining the droplet size and its distribution during the course of spray event is challenging as typically an actuation is complete in about a tenth of a second. Further to this, regulatory guidance also demands that particle size of drug in droplet also needs to be determined for a better understanding of how a nasal spray product interacts with the body. This webinar focuses on how Malvern Panalytical technologies are helpful in better understanding of parameters like droplet size, drug particle size, shape etc.

Interested in our particle size analysis series of webinars, please scroll below.Agenda

What will I learn 

1. Investigating drug delivery characteristics with respect to particle size

2. Droplet size determination using Laser Diffraction

3. Quantification of particle size and shape using automated image analysis

4. Understanding bioequivalence using MDRS


Like what you just read? You can find similar content on the communities below.

Analysis & Separations

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free